Therapeutic Classification: antivirals
Pharmacologic Classification: NS5A inhibitors, protease inhibitors
Elbasvir
Absorption: Well absorbed following oral administration.
Distribution: Extensively distributed to tissues.
Protein Binding: >99.9%.
Half-Life: 24 hr.
Grazoprevir
Absorption: Well absorbed following oral administration.
Distribution: Extensively distributed to tissues.
Protein Binding: >98.8%.
Half-Life: 31 hr.
Contraindicated in:
Use Cautiously in:
GI: ↑liver enzymes, abdominal pain, diarrhea, HEPATIC DECOMPENSATION/FAILURE, nausea
Misc: fatigue, ANGIOEDEMA, hepatitis B virus reactivation
Drug-drug:
Drug-Natural Products:
Patients with HCV genotype 1a infection should be tested for the presence of virus with NS5A resistance-associated polymorphisms prior to initiation of therapy to determine the most appropriate dosage regimen and duration of therapy
Lab Test Considerations: